Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Aigen Investment Management LP

Aigen Investment Management LP boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 780.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,367 shares of the biopharmaceutical company’s stock after acquiring an additional 5,644 shares during the quarter. Regeneron Pharmaceuticals makes up 0.8% of Aigen Investment Management LP’s investment portfolio, making the stock its 8th biggest position. Aigen Investment Management LP’s holdings in Regeneron Pharmaceuticals were worth $4,535,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock worth $495,639,000 after purchasing an additional 22,538 shares during the last quarter. Swiss National Bank boosted its holdings in Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock worth $338,079,000 after purchasing an additional 2,000 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after purchasing an additional 1,108 shares during the last quarter. Finally, National Pension Service raised its holdings in shares of Regeneron Pharmaceuticals by 4.0% during the fourth quarter. National Pension Service now owns 232,450 shares of the biopharmaceutical company’s stock worth $165,581,000 after purchasing an additional 8,833 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 1.4 %

REGN stock opened at $675.49 on Wednesday. The stock has a market capitalization of $73.85 billion, a P/E ratio of 17.65, a P/E/G ratio of 2.34 and a beta of 0.08. The business has a fifty day moving average price of $697.13 and a 200-day moving average price of $859.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $11.86 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Bank of America reaffirmed an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Finally, Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.